SOUTH SAN FRANCISCO, Calif. / Apr 30, 2024 / Business Wire / Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
In addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CAH, as an illustration of outcomes of current pediatric CAH disease management, was accepted for poster presentation at the PES conference.
PES 2024 Poster Presentation Details:
Title: Baseline Characteristics of CAHptain: A Phase 2 Dose-finding Study of Tildacerfont in Children with Classic Congenital Adrenal Hyperplasia
Abstract Number: 6899
Poster Session: 2
Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT
Presenter: Mimi S. Kim, M.D., Co-Director, Congenital Adrenal Hyperplasia Comprehensive Care Clinic, Children’s Hospital Los Angeles
Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
Abstract Number: 6898
Poster Session: 2
Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT
Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence
The poster presentations will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.
| Last Trade: | US$0.11 |
| Daily Volume: | 0 |
| Market Cap: | US$4.650M |
December 10, 2024 November 11, 2024 August 12, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
